The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 8 of the 112 sources its claims cite were checked for support.
Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review
Open accessAbstract
Introduction: The availability and affordability of safe, effective, accessible, and high-quality essential medicines is a critical benchmark for achieving the right to good health, and it is also one of the goals of the global health development agenda. To that end, it is critical to conduct rigorous studies to identify the major challenges confronting developing countries, particularly those in Africa. Objective: The purpose of this review was to identify the major challenges that Africans face in obtaining reasonably priced and readily available essential medicines. Methods: Generally the Boolean operators "AND" and "OR" were employed. Making progress also involves using duplicate checks, field definitions, and comparisons of articles and criteria. The analysis included all English-language papers published in any African country between 2005 and 2022, depending on the year of publication. The technique searches electronic databases for key phrases related to essential medication availability and affordability, such as PubMed, Web of Science, Scopus, Science Direct, Plos Medicine, and Google Scholar. Results: A total of 91 articles; by using search engines and handpicking including duplicates, were primarily searched. The electronic database search earned 78 articles while only eleven studies met the criteria for review and were reviewed of which 5 (50%) were from East African countries. Inadequate human resources, financial constraints, high cost of available medications on the market, poor inventory management, manual consumption forecasting, inefficiencies in drug registration, and trade-related aspects of intellectual property rights agreement regulations are all obstacles to the availability of essential medicines in African nations. Conclusion: This review revealed that in Africa, the availability and affordability of essential medicines face numerous challenges. The primary challenge, according to the review research, is a lack of adequate financing to pay for an appropriate set of essential medications, which account for a significant portion of household spending.
Overview
CoChat Summary
TL;DR
This scoping review synthesizes 11 studies on barriers to essential medicine availability and affordability in African countries, identifying financing, pricing, supply-chain, human-resource, regulatory, and governance challenges. It concludes that availability remains below the WHO 80% benchmark and that medicines are often unaffordable, especially for poor households.
Key findings
- The review included 11 studies: 5 qualitative, 4 cross-sectional, and 2 mixed; 5 (50%) were from East African countries. Reported barriers included inadequate human resources, financial constraints, high market prices, poor inventory management, manual consumption forecasting, inefficient drug registration, and TRIPS-related regulations.
- Availability was low: in one 8-country survey of 3,353 hospitals and primary care facilities, mean availability of 12 essential medicines ranged from 22% to 40%; in Uganda, average availability of tracer drugs in public pharmacies was 63.3%; in South Africa, public-sector median availability of lowest-price brands and generics was 10% and 75%, while private-sector median availability was 28.6%.
- Affordability was poor: high-cost essential medicines required the lowest-paid government employee to work 15 days for a one-month supply; branded medicines were 13.8 times more expensive than generics, and generics and brands were purchased at 2.9 and 32.6 times international reference prices, respectively. In Ethiopia, 45.6% of non-buyers cited unavailability, 45.7% cited expense, 8.7% cited ineffectiveness, and 11.8% forwent treatment due to cost.
- The review reports that African-region median availability of essential medicines was 61.5% versus 27.3% for nonessential medicines; public-sector median availability was 40% and private-sector 78.1%, compared with 6.6% and 57.1% for nonessential medicines. The conclusion states availability does not exceed 65% and purchasing costs are unaffordable.
Methods
- Scoping review searching PubMed, Web of Science, Scopus, Science Direct, Plos Medicine, and Google Scholar, using Boolean operators “AND” and “OR,” field specifications, duplicate checks, and article/criteria comparisons.
- Inclusion covered English-language, open-access PDF articles on challenges to essential medicine availability, affordability, and accessibility in African countries; the abstract and inclusion criteria state 2005–2022, while the search strategy states 2005–2023. Dissertations, abstracts, editorials, clinical views, non-African studies, and abstract-only publications were excluded.
- Methodological quality was assessed with PRISMA and an EBL critical appraisal tool; three reviewers independently assessed full texts, with 85.7% inter-observer agreement. Validity thresholds were <75% low quality, 75–90% moderate, and >90% high; most included studies were medium reliability, with 2 (20%) rated excellent.
Limitations
- Stated by the paper: the review does not examine one influencing factor in detail or all influencing factors, but analyzes factors frequently mentioned in the reviewed articles; it also does not assess challenges across the continent as a whole and ignores national economies, policies, and regulations affecting availability and affordability.
- Evident from the text: the search and inclusion numbers are inconsistent—the abstract reports 91 articles primarily searched and 78 from electronic databases, while the Results section reports 88 studies initially retrieved and 11 reviewed—and the date range is reported as both 2005–2022 and 2005–2023.
- Evident from the text: only 11 studies were included, most were hospital-based, 5 (50%) were from East African countries, and most were rated medium reliability, limiting continent-wide generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 4 Not valid · 80 Not checked · 32 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Transportation is widely acknowledged as a challenge in obtaining pharmaceutical care due to road closures, poor road construction, and transportation shortages; however, it is underexplored in terms of the clarity needed for tackling more immediate health and transportation policy interventions.27,28”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Transportation
What the sources say
- Partly supportedcites [27] Chandani, 2012, Am J Trop Med Hyg sourceExperimental — accuracy not yet measured
The Results section, “Precondition 4: Availability of appropriate transportation” (page unavailable), reports that community health workers identified unavailable or unreliable transport, distance, and rainy-season travel as obstacles to obtaining medicines. It notes dirt roads but does not identify road closures or poor road construction as causes. The evidence also concerns workers collecting medicine supplies, rather than patients obtaining pharmaceutical care generally. (LLM, conf=0.86)
- Not checked yetcites [28] Kanda, 2015, Int J Acad Res Account Financ Mang Sci source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Other challenges in the medicine registration process include noncompliance with medicine registration guidelines in different countries, prolonged medicine registration time or dossier rejection, poor medicine dossier assessment, cost of current good manufacturing practice inspection, and quality testing procedures that did not keep pace with the increasing demand of pharmaceutical industries for”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Drug Registration and Regulation
What the sources say
- Not checked yetcites [36] Kefale B. Explore the challenge in medicines registration process in Ethiopia: qualitative phenomenological study; 2020.
- Partly supportedcites [38] Moran, 2011, PLoS Med sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) supports the general framing: a 2010 WHO study found 90% of sub-Saharan African MRAs 'in a situation which did not allow them to adequately carry out regulatory functions,' and 'growth in African regulatory capacity is not keeping up with these new challenges' posed by the growing demand to assess novel ND products. The Discussion likewise calls the current system inefficient and resource-wasteful, and the proposals list joint good manufacturing practices plant inspections and joint dossier review. But no passage in our copy — searched for 'quality testing procedures', 'quality control laboratories', 'batch release/testing' — identifies quality testing procedures as a registration challenge that failed to keep pace with demand; that specific element of the citing sentence is not attributable to this paper. (LLM, conf=0.70)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low investment in essential medicines for health, a lack of comprehensive health financing policies and strategic plans, extensive out-of-pocket payments, a lack of social safety nets to protect the poor, poor financial management, inefficient resource allocation and use, and weak mechanisms for coordinating partner support constrain health financing in the African region.30,41”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > DovePress 453
What the sources say
- Could not verifycites [30] Droti, 2019, BMJ Glob Heal sourceExperimental — accuracy not yet measured
The Discussion says the surveyed countries had very limited public-sector budgets for medicine procurement, but it does not identify poor financial management as a constraint on health financing. Searches for financial management and resource allocation found no passage addressing that point. (LLM, conf=0.72)
- Supportedcites [41] Kirigia, 2008, BioMed Cent source
The Challenges section explicitly lists weak financial management among the characteristics of health financing in the African Region. That supports the attributed claim that poor financial management constrains health financing there. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This review revealed that in Africa, the availability and affordability of essential medicines face numerous challenges.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“trade-related aspects of intellectual property rights agreement regulations are all obstacles to the availability of essential medicines in African nations.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
56 more claims
Create a free account to see all 123 claims and to verify the 104 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 38
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
“The electronic database search earned 78 articles”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Results
“the preliminary information retrieval system across all databases resulted in 88 studies (68 from Pub Med).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“eleven studies met the criteria for review and were reviewed of which 5 (50%) were from East African countries.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > Abstract
Reported 50 · recomputed 45.454545
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“the majority of studies were of medium reliability, with 2 (20%) being of excellent quality.”
§ Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review > The Listed Studies' Methodological Quality
Reported 20 · recomputed 18.181818
Citations
Cites
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & the PRISMA-P Group (2015) · BMJ · doi:10.1136/bmj.g7647 · Cited by 13,120
Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61762-6 · Cited by 928 · cited 2×
“Medicines consume up to 20–60% of health expenditure in developed and transitional countries, and in developing African nations, nearly 90% of the population buys medicines out of pocket, making medicines the second-largest item of family spending after food.(32) Over 50 price and affordability surveys were conducted…”
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661 · cited 3×
“To be available and affordable drugs should be used in a suitable, safe, cost-effective, secure, and accessible way.(7) Given that from 2001 to 2007, just 30% of all both private and public health facilities in African countries had access to vital medicines, more than 70% of the population in Africa was impacted.”
InfluentialMendis, S. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.06.033647 · Cited by 487 · cited 3×
“The World Health Organization and Health Action International recommend using the LPGW’s income as a benchmark for comparing the cost of medication care to the availability of medications.(2,20) Since the current global minimum salary is US $ per day, the lowest-paid unskilled government employee’s daily wage will be…”
InfluentialA critical appraisal tool for library and information research
Glynn, L. (2006) · Library Hi Tech · doi:10.1108/07378830610692154 · Cited by 345 · cited 2×
“The calculation for overall validity was: (Y+N +U=T); If Y/T ≥75% or if N+U/T ≤ 25% then it can safely conclude that the study is valid.(23) A score of less than 75% was considered low quality, 75% to 90% was considered moderate quality, and more than 90% was considered high quality.”
Modisakeng, C., Matlala, M., Godman, B., & Meyer, J. C. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05080-1 · Cited by 130 · cited 2×
“According to the World Bank, approximately 80% of the African continent’s population, primarily those in the middle and lower income brackets, rely on public health facilities to access health care.(25) Several factors have been linked to affecting the accessibility of essential medicines in Africa’s public and privat…”
Revisiting the issue of access to medicines in Africa: Challenges and recommendations
Adebisi, Y. A., Nwogu, I. B., Alaran, A. J., Badmos, A. O., Bamgboye, A. O., Rufai, B. O., Okonji, O. C., Malik, M. O., Teibo, J. O., Abdalla, S. F., et al. (2022) · Public Health Challenges · doi:10.1002/puh2.9 · Cited by 111 · cited 6×
“Many people living in Africa have a problem with accessing medicines and this undoubtedly contributes to the poor health metrics of most countries in the region.(4) The availability and cost of medications are considered two of the most crucial factors for providing healthcare users with quality healthcare, along with…”
InfluentialHealth challenges in Africa and the way forward
Kirigia, J., & Barry, S. (2008) · International Archives of Medicine · doi:10.1186/1755-7682-1-27 · Cited by 110 · cited 4×
“Extreme shortages of highly qualified health professionals, rooted in African countries, have been exacerbated by disparities in labor distribution and brain drain in this crisis, jeopardizing the delivery of effective public health interventions to those in need, particularly in remote rural areas.(16,41) Professiona…”
InfluentialMajor Public Health Problems in Nigeria: A review
Muhammad, F., Abdulkareem, J. H., & Chowdhury, A. A. (2017) · South East Asia Journal of Public Health · doi:10.3329/seajph.v7i1.34672 · Cited by 79 · cited 1×
“43”
Chandani, Y., Noel, M., Pomeroy, A., Andersson, S., Pahl, M. K., & Williams, T. (2012) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2012.11-0781 · Cited by 74 · cited 1×
“27,28 Outlined that transportation infrastructure affects the total supply chain performance of pharmaceuticals due to poor infrastructure construction, development, heavy traffic over-crowding in large cities, and poor availability in rural areas of Africa.”
Research works printed but not linked: 16
- World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies WHO Guideline on Country Pharmaceutical Pricing Policies. World Health Organization; 2020:1–70.
- Bruno, 2015, J Pharm Care Heal Syst, 1, 10.4172/jpchs.s2-006 · doi:10.4172/jpchs.s2-006
- Latifah, 2019, Rev Artic, 10, 67
- Fredrick, 2016, IOSR J Business Manag, 18, 63, 10.9790/487x-1810066375 · doi:10.9790/487x-1810066375
- Obuaku, 2014, Afr Soc Rev, 18, 42
- Zuma, 2019, World J Pharm Res, 8, 1532, 10.20959/wjpr20199-15303 · doi:10.20959/wjpr20199-15303
- Abiye, 2013, J Appl Pharma Sci, 3, 101, 10.7324/japs.2013.31017 · doi:10.7324/japs.2013.31017
- Irene, 2016, J Health Med Nurs, 27, 45
- Mendis, 2007, Lancet, 85, 279, 10.2471/blt · doi:10.2471/blt
- World Health Organization. Measuring affordability and price availability, components. In: Medicine Prices, Measuring Affordability and Price Availability, Components. World Health Organization; 2008:1–310.
- Machemedze MMR, Munyuki E. Literature review on bottlenecks to essential medicines production and procurement in East and Southern Africa; 2013:1–23.
- Modisakeng, 2020, MBC Heal Serv Res, 1, 1
- Osei-Assibey, 2017, J Biomed Pharm Res, 6, 100
- 2019, Ensuring Access to Medicines in East Africa: Lessons from India
- Baker, 2009, Am Med Assoc J Ethics, 2009, 527
- Mohammadshahi, 2019, Shiraz E Medical J, 20, 1, 10.5812/semj.87079.review · doi:10.5812/semj.87079.review
Cited by
Okesanya, O. J., Amisu, B. O., Adigun, O. A., Ahmed, M. M., Agboola, A. O., Kab, T., Eshun, G., Ukoaka, B. M., Oso, T. A., Ogaya, J. B., et al. (2025) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-024-00236-x · Cited by 34
“Over time, this results in a vicious cycle where the financial pressure on the healthcare system undermines the overall economic development of the region [86, 87].”
Gaetano, S. D., Ponzo, E., Midiri, A., Mancuso, G., Filippone, D., Infortuna, G., Zummo, S., & Biondo, C. (2025) · Hygiene · doi:10.3390/hygiene5020018 · Cited by 42
Disparities in availability of new cancer drugs worldwide: 1990-2022
Li, M., Ka, D., & Chen, Q. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-015700 · Cited by 28
“34 35 For example, countries may not have sufficient funds to cover new cancer drugs in their national formulary or to support infrastructure for administrating specialty cancer therapies.”
Personalized medicine and health equity: overcoming cost barriers and ethical challenges
Francisco, K. K. Y., Apuhin, A. E. C., Maravilla, N. M. A. T., Byers, M. C., Karim, H. B. A., Tan, M. J. T., & AlDahoul, N. (2025) · International Journal for Equity in Health · doi:10.1186/s12939-025-02710-0 · Cited by 30
“Challenges such as unestablished drug regulatory programs, logistics, weak health systems, and resource scarcity make acquiring these medications nearly impossible [40, 41].”
The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa
Madu, C. V., Alum, E. U., Aloh, H. E., Ugwu, O. P.-C., Obeagu, E. I., Uti, D. E., Egba, S. I., Ukaidi, C. U. A., & Alum, N. B. (2025) · Medicine · doi:10.1097/md.0000000000042300 · Cited by 34
Metadata
- Authors
- Yenet, A., Nibret, G., & Tegegne, B. A.
- Affiliations
- Debre Markos University (ET)
- Corresponding author
- Yenet, Aderaw
- Nibret, Getinet
- Tegegne, Bantayehu Addis
- Venue
- ClinicoEconomics and Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2023-06
- Volume
- Volume 15
- Pages
- 443-458
- ISSN
- 1178-6981 (ISSN-L)
- PMC
- PMC10276598
- OpenAlex
- W4380630724
- Semantic Scholar
- ac3ee2843ccf5f72c24e512e988b5d506ce6a96a
- Cited by
- 202
- References
- 22
- Citations by year
- 2026: 83 · 2025: 73 · 2024: 43 · 2023: 3
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- ClinicoEconomics and Outcomes Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Keywords
- essential medicines, drug availability, drug affordability, Africa, health care financing, drug pricing, inventory management, drug registration, intellectual property, health workforce shortage, household health expenditure, right to health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review. https://app.cochat.ai/papers/10.2147/ceor.s413546
- The paper
- Yenet, A., Nibret, G., & Tegegne, B. A. (2023). Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review. ClinicoEconomics and Outcomes Research. https://doi.org/10.2147/ceor.s413546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

